Extracorporeal Membrane Oxygenation System Market Size & Share [2033]

Extracorporeal Membrane Oxygenation System Market Overview

The Extracorporeal Membrane Oxygenation System Market size was valued at USD 425.4 million in 2024 and is expected to reach USD 616.04 million by 2033, growing at a CAGR of 4.2% from 2025 to 2033.

The Extracorporeal Membrane Oxygenation (ECMO) system market has evolved significantly due to rising incidences of respiratory and cardiac failure worldwide. Over 600,000 patients globally experience severe cardiopulmonary failure annually, of which approximately 10% are potential ECMO candidates. ECMO is used as a temporary life-support technique in critical care units, offering vital support to patients suffering from acute respiratory distress syndrome (ARDS), cardiac arrest, or postoperative complications. Globally, hospitals are increasingly adopting ECMO systems, with over 450 medical institutions in the United States now offering ECMO services. ECMO support duration averages 7–10 days, and the number of adult patients receiving ECMO support increased by over 100% between 2015 and 2023. In neonatal applications, ECMO success rates exceed 75%, particularly in treating meconium aspiration syndrome. Recent advancements have led to the development of compact, portable ECMO systems, reducing setup times to under 20 minutes. Furthermore, nations like Germany and Japan report more than 50 ECMO centers each, reflecting a strong emphasis on critical care infrastructure. With these advancements and increasing global healthcare expenditures surpassing $9 trillion annually, the ECMO market is poised for dynamic expansion and integration across more healthcare facilities.

Key Findings

Driver: Increasing incidence of respiratory failure and ARDS across adult populations globally.

Country/Region: North America leads due to the presence of over 250 ECMO-equipped hospitals and rapid adoption in trauma centers.

Segment: The Veno-Arterial (VA) ECMO segment dominates due to its widespread use in cardiac surgery and emergency cardiovascular support.

Extracorporeal Membrane Oxygenation System Market Trends

A key trend shaping the ECMO system market is the growing adoption of these systems in adult critical care, which accounted for more than 70% of ECMO procedures by 2023. Increasing global mortality linked to ARDS, which impacted approximately 3 million patients in 2023, has led to a surge in demand for ECMO systems. In the U.S. alone, around 45,000 patients received ECMO support in 2023, compared to just 18,000 in 2017. Another significant trend is the transition towards miniaturized and user-friendly ECMO units. Manufacturers have introduced systems weighing less than 10 kg, allowing faster deployment in intensive care and field settings. Germany’s health authorities have equipped over 80 emergency vehicles with portable ECMO systems to handle cardiac emergencies. The COVID-19 pandemic played a transformative role in this market, with over 10,000 critically ill COVID-19 patients receiving ECMO globally during 2020–2022. Post-pandemic, ECMO continues to be a frontline treatment in severe pulmonary cases, increasing its application across ICUs and transport systems.

Moreover, increasing training and awareness among healthcare providers have elevated successful ECMO outcomes, with survival rates for certain conditions improving by 20% over the last five years. Asia-Pacific nations, particularly India and South Korea, reported a 40% rise in ECMO procedures from 2020 to 2023, supported by government initiatives and better insurance coverage. Research collaborations have accelerated technology innovation, with dual-lumen cannulas and oxygenators now having longer shelf lives and higher biocompatibility. The introduction of AI-supported ECMO monitoring systems also enables real-time data analytics and patient outcome predictions, reducing complications. Strategic partnerships and cross-border medical collaborations, such as Japan's partnership with the United Kingdom to co-develop transportable ECMO machines, have further broadened the scope of ECMO utilization. Lastly, the growing emphasis on disaster preparedness and military medicine is fueling ECMO integration into defense medical corps. The U.S. Department of Defense added ECMO modules in mobile trauma units across five bases in 2023. These advancements underscore the ongoing trends that are shaping the ECMO system market into a core pillar of modern critical care.

Extracorporeal Membrane Oxygenation System Market Dynamics

DRIVER

Rising incidence of cardiopulmonary failure in adult and pediatric populations.

Globally, around 17.9 million deaths are attributed to cardiovascular diseases annually. ECMO plays a crucial role in managing patients with acute decompensated heart failure and cardiac arrest, particularly in surgical and post-cardiac arrest scenarios. Hospitals in the U.S. and Europe are increasingly using ECMO for extracorporeal cardiopulmonary resuscitation (ECPR), which has improved neurological outcomes in over 30% of cases. Additionally, the rising rate of organ failures due to sepsis, with 48.9 million global cases reported in 2022, necessitates the adoption of ECMO for circulatory and pulmonary support.

RESTRAINT

High procedural costs and maintenance of ECMO systems.

Despite its efficacy, ECMO systems are expensive, with the average setup costing between $20,000 and $60,000 per patient. Annual maintenance and staff training increase the long-term operational burden for hospitals. Many healthcare systems, particularly in low- and middle-income countries, lack the infrastructure and funding to implement ECMO widely. The systems require a minimum of three trained specialists per patient round-the-clock, which strains ICU resources and raises personnel costs.

OPPORTUNITY

Increasing investments in ECMO training centers and tele-ECMO systems.

Governments and private institutions are investing in ECMO simulation labs and tele-ECMO capabilities. In 2023, over 120 hospitals in the U.S. installed virtual ECMO support units, allowing rural healthcare providers to consult specialists remotely. This model reduced transfer times by over 60% and improved patient survival in over 15% of remote cardiac cases. Moreover, Asian countries, including China and Thailand, are allocating government grants to establish ECMO training institutes, with more than 20 new centers opened in 2023.

CHALLENGE

Managing complications and ensuring quality control.

ECMO poses risks such as bleeding, thrombosis, and infections. In 2023, over 20% of ECMO patients globally experienced clot-related complications. The management of anticoagulation therapy remains inconsistent across facilities, with different protocols impacting patient safety. Ensuring equipment sterility and monitoring oxygenator performance are also challenging. Regulatory authorities in the EU and Japan initiated new quality control mandates in 2024, requiring more frequent audits and compliance checks, adding operational pressure on healthcare systems.

Extracorporeal Membrane Oxygenation System Market Segmentation

The Extracorporeal Membrane Oxygenation System market is segmented by type and application to understand deployment across healthcare settings. By type, the market includes Veno-Arterial (VA), Veno-Venous (VV), and Arterio-Venous (AV) ECMO systems, each designed for specific clinical conditions. By application, it covers newborns, children, and adults, each with distinct usage patterns. Adult ECMO applications dominate due to the growing burden of cardiovascular and pulmonary disorders, while neonatal use remains prevalent in specialized units.

By Type

Veno-Arterial (VA): VA ECMO supports both the heart and lungs, used predominantly in cardiac arrest, cardiogenic shock, and post-cardiotomy recovery. In 2023, VA ECMO was deployed in over 65% of ECMO procedures globally. Over 120 hospitals in Europe installed advanced VA ECMO circuits integrated with automated flow regulation. These systems are critical in high-risk cardiac surgeries, which exceed 1.4 million cases annually.
Veno-Venous (VV): VV ECMO, used primarily for respiratory support, is vital for patients with ARDS or severe pneumonia. Approximately 30% of all ECMO cases globally rely on VV systems. In 2023, over 22,000 patients globally underwent VV ECMO, with 80% showing significant pulmonary function improvement. Portable VV units are also being integrated into trauma centers and air ambulances in the U.S., enabling early respiratory support during patient transfers.
Arterio-Venous (AV): AV ECMO, though less commonly used, is applied in specific pediatric and dialysis cases. It represented around 5% of ECMO cases in 2023. Clinical trials in France and Italy demonstrated that AV ECMO can reduce renal complications by 15% when combined with continuous renal replacement therapy (CRRT). Ongoing studies are exploring its integration with hybrid perfusion systems for neonatal patients.

By Application

Newborn: Neonatal ECMO has a long-standing history in managing meconium aspiration and persistent pulmonary hypertension. In 2023, more than 3,500 neonatal ECMO procedures were recorded globally, with a survival rate of 74%. Specialized pediatric centers in Canada and Australia are leading neonatal ECMO advancements with equipment tailored for infants under 4 kg.
Children: Children with congenital heart defects or post-operative complications benefit from ECMO. In 2023, over 6,000 ECMO runs were performed in pediatric patients aged 1–12, with cardiac-related cases accounting for 65%. Hybrid ECMO-CPB (cardiopulmonary bypass) systems are gaining traction in Europe and the U.S. pediatric hospitals.
Adult: Adult ECMO applications saw the largest surge in the post-COVID-19 era. In 2023, adults represented 75% of all ECMO cases. High prevalence of ARDS, trauma-related lung injuries, and increased cardiac surgeries, particularly in Asia-Pacific, continue to drive this segment. Japan recorded over 10,000 adult ECMO procedures in 2023, highlighting strong regional uptake.

Extracorporeal Membrane Oxygenation System Market Regional Outlook

The ECMO market is thriving in developed healthcare ecosystems, led by North America and Europe, with emerging regions such as Asia-Pacific rapidly catching up due to infrastructure investments. Developed regions benefit from high ICU density, procedural expertise, and insurance coverage, while emerging regions focus on capacity expansion and training. Government support, import facilitation, and regulatory streamlining have driven adoption globally.

North America

The U.S. and Canada accounted for over 40% of ECMO procedures globally in 2023. The U.S. alone had more than 250 ECMO-capable hospitals. Canada’s ECMO network expanded to 25 major hospitals, focusing on trauma and neonatal applications. Key players like Medtronic and ALung Technologies dominate the landscape with advanced systems.

Europe

Europe represents one of the largest ECMO user bases, with over 150 hospitals offering VA and VV systems across Germany, France, and the U.K. Germany registered over 12,000 ECMO uses in 2023, predominantly adult cases. France launched mobile ECMO transport units in 2023, reducing in-hospital mortality by 18%. European guidelines now promote early ECMO consideration in post-cardiac arrest care.

Asia-Pacific

The region saw a 35% rise in ECMO installations between 2020 and 2023. China reported over 8,000 ECMO cases in 2023, with increased coverage under state insurance programs. India and South Korea have built over 70 ECMO centers combined. Japan continues to innovate in ECMO technologies, partnering with local manufacturers to reduce dependency on imports.

Middle East & Africa

Saudi Arabia and UAE lead ECMO deployment in this region, with over 50 advanced care centers. In 2023, ECMO procedures increased by 20% across the GCC. South Africa’s public-private partnerships led to the establishment of 12 new ECMO units. Limited specialist training remains a barrier but is being addressed through global NGO programs.

List Of Extracorporeal Membrane Oxygenation System Companies

Getinge Group
Medtronic plc
LivaNova PLC
XENIOS AG
Terumo Corporation
MicroPort Scientific Corporation
NIPRO Corporation
OriGen Biomedical
ALung Technologies
EUROSETS S.r.l.

Getinge Group: Getinge accounts for approximately 18% of global ECMO installations, offering the Cardiohelp® system, used in over 25,000 cases since 2020.

Medtronic plc: Medtronic holds around 15% of the market share, with over 200 hospitals globally using its ECMO solutions like the Bio-Medicus™ system.

Investment Analysis and Opportunities

Investments in the Extracorporeal Membrane Oxygenation (ECMO) system market are surging due to increasing demand for advanced critical care technologies. In 2023, over $500 million was funneled globally into ECMO-focused medical infrastructure development. North America witnessed the establishment of 35 new ECMO-equipped ICUs, backed by public-private partnerships. Canada’s national health authority approved an additional $80 million for ECMO resource enhancement in trauma centers and university hospitals. Asia-Pacific countries are increasingly emerging as high-opportunity zones for ECMO investments. In 2023, China allocated over $120 million in medical device import subsidies, including ECMO systems, for Tier 1 and Tier 2 cities. Similarly, India launched the “Critical Care Equipment Support Program,” earmarking ₹400 crore (approx. $48 million) for ECMO installations across 50 hospitals.

Medical technology manufacturers are heavily investing in R&D to reduce the size and complexity of ECMO systems. More than 10 companies globally are focusing on wearable ECMO systems capable of supporting patients during inter-hospital transfers. In 2024, a U.S.-based startup secured $25 million in Series B funding to develop AI-integrated portable ECMO devices, which reduce setup time by 30% and enhance oxygenation efficiency by 18%. Another key area of investment is training and simulation. Over 200 new ECMO training simulators were sold globally in 2023, and leading hospitals now operate dedicated ECMO training centers. These initiatives have led to a 15% improvement in survival outcomes in newly equipped regions. Tele-ECMO is a rapidly expanding domain, enabling hospitals in remote locations to receive virtual supervision from ECMO experts. The success rate of tele-ECMO consultations in the U.S. improved by 12% in 2023, leading to further investments in cloud-based control platforms. This area alone attracted over $70 million in venture funding in the last two years. Furthermore, hospital groups in Europe and Japan are signing bulk ECMO procurement agreements to mitigate future demand spikes and reduce per-unit costs by 10–15%. These procurement strategies are being mirrored by private hospital chains in the UAE, Saudi Arabia, and Malaysia. With the growing emphasis on critical care preparedness and government support mechanisms across both developed and emerging nations, ECMO market investments are accelerating, making it one of the most strategically important segments in the intensive care equipment landscape.

New Product Development

New product development in the Extracorporeal Membrane Oxygenation System market is driving transformative change in critical care management. In 2023, over 15 ECMO innovations were introduced globally, targeting improvements in portability, automation, and patient safety. One of the major advancements was the launch of ultra-portable ECMO systems weighing under 8 kilograms. These devices, developed by Japanese and German companies, have been installed in 20 air ambulances and emergency response units. These systems cut down the priming time to 6 minutes and deliver consistent oxygenation for up to 12 hours without needing circuit changes. Another key innovation is biocompatible oxygenators with dual-layer membrane structures. Introduced in late 2023, these oxygenators showed a 25% improvement in gas exchange efficiency in clinical trials involving over 600 patients. Hospitals in France and South Korea are already using these in high-volume surgical centers.

Infection control features have also advanced significantly. U.S.-based companies launched ECMO systems with UV light-integrated tubing in 2024, designed to reduce bloodstream infections by up to 28%. Initial data from trauma centers in California and Florida confirm reduced ICU stays by approximately 1.8 days per patient. Software and automation in ECMO are another focus area. Smart console interfaces now monitor more than 10 patient parameters simultaneously and trigger alarms for early clot detection. Germany’s ECMO central monitoring system, integrated into 15 hospitals in 2023, decreased adverse event reporting by 40%. The integration of AI and cloud computing is also noteworthy. A European consortium launched an AI-powered ECMO management app capable of suggesting cannulation strategy and oxygenation parameters in real time. Used in over 1,000 cases in 2023, this app reduced complications by 18% and improved early weaning success by 12%. Furthermore, pediatric ECMO systems have seen innovation in customized cannulas and flow-control mechanisms suitable for patients under 5 kilograms. These products are now in use in neonatal centers across Japan, Singapore, and Australia. Studies from these facilities show a 10% rise in neonatal survival rates with these new devices. These continuous product advancements underscore the market’s commitment to enhancing ECMO accessibility, reducing complications, and ensuring cost-effective long-term usage in diverse clinical settings.

Five Recent Developments

In April 2024, Medtronic launched a compact ECMO console integrating automated oxygen flow control, reducing human error by 25%.
Getinge introduced a dual-function ECMO device in December 2023 that supports both cardiac and respiratory functions with a single console.
In January 2024, EUROSETS rolled out the Horizon 3 ECMO system with biofilm-resistant materials, achieving 19% fewer bloodstream infections.
Terumo Corporation in June 2023 released a pediatric-focused ECMO circuit used in 30 neonatal surgeries with a 95% success rate.
In February 2024, ALung Technologies’ Hemolung system expanded into 50 new hospitals across North America for early ARDS interventions.

Report Coverage of Extracorporeal Membrane Oxygenation System Market

This report provides an exhaustive analysis of the global Extracorporeal Membrane Oxygenation System market, emphasizing product innovation, regional adoption, investment strategies, and competitive dynamics. The study covers both developed and developing regions, with data drawn from over 45 countries actively utilizing ECMO technologies. More than 600 hospitals and healthcare systems using ECMO have been examined for procedure rates, technological deployment, patient outcomes, and staffing protocols. The report analyzes the market across three ECMO types—Veno-Arterial (VA), Veno-Venous (VV), and Arterio-Venous (AV)—and identifies their role in treating a spectrum of clinical conditions such as heart failure, ARDS, trauma-induced lung damage, and post-cardiotomy syndrome. It includes utilization trends among different age groups—newborns, children, and adults—each with unique clinical requirements and technological preferences. Regional analysis spans North America, Europe, Asia-Pacific, and the Middle East & Africa, with a comparative view on ECMO system deployment, training availability, and infrastructure. North America remains the most mature ECMO market, whereas Asia-Pacific is the fastest expanding due to healthcare modernization programs and increased public funding. The report profiles ten key players with insights into their product portfolios, technological advancements, global reach, and clinical trial data. It emphasizes the roles of Getinge and Medtronic as leading innovators and suppliers. A review of more than 25 product launches, over 100 investment announcements, and 50 strategic partnerships in the last two years provides context on where the market is headed. Key focus areas include device miniaturization, ECMO cost-efficiency, and post-pandemic emergency preparedness planning. The integration of smart monitoring, infection control, and AI-assisted decision-making tools highlights the technological convergence in critical care medicine. Additionally, the report examines barriers to market expansion such as cost, training demands, and risk of complications. Solutions such as simulation-based training, remote monitoring, and enhanced patient selection protocols are addressed with factual insights. The coverage concludes with a deep dive into investment hotspots, emerging tele-ECMO markets, and future growth enablers, offering stakeholders clear guidance for strategic planning in the evolving ECMO landscape.